Lumida
/RDNT
⌘K
RadNet Inc

RadNet Inc

RDNT
$62.19USD↓-1.27%-0.80 today

MARKET CAP

4.9B

P/E (TTM)

155.5x

FWD P/E

76.7x

DAY RANGE

$59 – $63

52W RANGE

$51
$86

AI Summary

Stalk
StalkMedium

Post-Capitulation exhaustion at the flush low has established a mean-reversion foundation. Small overlapping candles with long lower wicks hold above the April lows, and RSI remains flat near oversold. Price is pulling back into declining 9/21/50 EMAs without clear acceptance or rejection. Medium-term bias is bullish under mean-reversion permission, but short-term timing is neutral; we will stalk deferred buy into the EMA support zone pending a clean resolution.

  • ↑Q1 2026 revenue $230M (+22.1% YoY) and adjusted EBITDA $57M (+36.3%).
  • ↑Advanced imaging now represents 29.3% of procedure volume, boosting margins.
  • ↓Anticipates $30M same-center labor cost increases in 2026, squeezing margins.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

RadNet, Inc. (NASDAQ: RDNT) is a leading provider in the healthcare sector, specializing in outpatient diagnostic imaging services, including advanced imaging solutions like MRI, CT, and PET-CT. The company is well-positioned to benefit from the ongoing trends towards outpatient care and increasing demand for advanced imaging. By investing in technology, including AI-driven solutions, RadNet aims to enhance operational efficiency and improve patient outcomes while expanding its service offerings to meet the diverse needs of a growing patient demographic.

Bull says

  • ↑Q1 2026 revenue $230M (+22.1% YoY) and adjusted EBITDA $57M (+36.3%).
  • ↑Advanced imaging now represents 29.3% of procedure volume, boosting margins.
  • ↑Raised 2026 guidance: imaging revenue +$30M, EBITDA +$5M, FCF +$7M.
  • ↑Cash balance $455M and $282M credit facility enable bolt-on deals.
  • ↑High earnings yield and positive earnings revisions underpin valuation.
  • ↑Acquisitions of Radiology Regional & Northwest Radiology add ~$117M revenue.

Bear says

  • ↓Anticipates $30M same-center labor cost increases in 2026, squeezing margins.
  • ↓Medicare reimbursement policy uncertainty could swing $4–5M in revenue.
  • ↓Integration of recent deals (e.g., Gleamer) risks delays and missed synergies.
  • ↓Severe weather cut revenue by ~$22M, adding volatility to results.
  • ↓High short interest signals investor skepticism and downward pressure.
  • ↓Weak dividend yield and valuation metrics may deter income-focused investors.

Investment themes with RDNT

Health Care Providers↓ -0.61%

UNH · CVS · HCA

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-11-2026bullish

Transcript signals

Bull points

  • We had a stronger than anticipated first quarter results when we set our financial guidance levels initially.
  • Despite being impacted by the severe winter weather conditions in January and February, lowering revenue by an estimated $13 million and adjusted EBITDA by an estimated $9 million, we were still able to achieve record first quarter revenue and adjusted EBITDA.
  • Relative to last year's first quarter, total company revenue increased 22.1% and adjusted EBITDA increased 36.3%.
Read full transcript analysis ›